Humanized monoclonal antibodies against human interleukin-5
US6056957A · kind A · utility
20Cited by
3References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 4, 1994 |
| Grant date | May 2, 2000 |
| Priority date | — |
| Expiry date | Aug 4, 2014 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A monoclonal antibody is provided which specifically binds to human interleukin-5. Also provided are a hybridoma which produces the monoclonal antibody; complementary DNAs which encode the heavy and light chain variable regions of the monoclonal antibody and CDRs therefrom; humanized monoclonal antibodies; and pharmaceutical compositions comprising the monoclonal antibody or anti-idiotypic antibodies directed against it, humanized monoclonal antibodies, binding fragments, binding compositions or single-chain binding proteins derived from the antibody and a physiologically acceptable carrier.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.